Brief: Neurocrine Biosciences Shares New Post-Hoc Data
27/06/2025 13:32
June 27 (Reuters) - Neurocrine Biosciences Inc NBIX.O: NEUROCRINE BIOSCIENCES PRESENTS NEW POST-HOC DATA ANALYSES FROM KINECT®-HD STUDY DEMONSTRATING SIGNIFICANT REDUCTION IN DISEASE BURDEN WITH INGREZZA® (VALBENAZINE) CAPSULES FOR HUNTINGTON'S DISEASE CHOREA Source text: ID:nPn8GkJb6a Further company coverage: NBIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall